HAE longThis set up looks really bullish. will be playing both gaps to the upside. $80c 3/18/2022 @3.85 could pay big time.
Next report date
Report period
Q4 2023
EPS estimate
0.83EUR
Revenue estimate
305.35 MEUR
2.27EUR
106.48 MEUR
1.08 BEUR
50.29 M
About Haemonetics Corporation
Sector
Industry
CEO
Christopher A. Simon
Website
Headquarters
Boston
Employees (FY)
3.03 K
Founded
1971
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
$HAE long$HAE forming a falling wedge approaching key support with RSI divergence on major timeframes, looks due for a bounce here. I like entry here with tight stop, 1 or 2 month time at least.
Haemonetics Receives FDA Clearance For NexSys PCS® With Persona(HAE: Haemonetics Corporation
2020-10-03 20:36:00
Haemonetics Receives FDA Clearance For NexSys PCS® With Persona(TM) Technology
HAEMONETICS! Haemonetics may correct at $100.80. In the long term, it will grow after the correction.
Haemonetics Reported First Quarter Fiscal 2021 Financial ResultsHaemonetics Reported First Quarter Fiscal 2021 Financial Results
themarketsignal.com
RSI of Haemonetics Corporation (NYSE:HAE) is 19.96 and the stock looks bullish. The company reported financial results for first quarter of fiscal 2021. In Q1-21 the company reported $196 million revenue, decreasin
HAE Shortbroke below daily support at 83.27, target 3/20 low (took position thinking i'd target the 3/18 low, but when looking at when i got home see that has such a long wick i think it's a stretch). SL just above the ~87.05 level that provided support over the lsat month
HAE. Price near support line$HAE - HAEMONETICS CORP. Engaged in blood donation activities. On the daily charts, the paper has reached a good level of support at $83. Starting from 19.06 the volume is significantly above the average, the RSI indicator came out of the oversold zone and shows a buy signal on the daily timeframe.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HAZ is 86.00 EUR — it has increased by 0.58% in the past 24 hours. Watch HAEMONETICS CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange HAEMONETICS CORP stocks are traded under the ticker HAZ.
HAEMONETICS CORP is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
HAZ stock is 0.58% volatile and has beta coefficient of 0.87. Track HAEMONETICS CORP stock price on the chart and check out the list of the most volatile stocks — is HAEMONETICS CORP there?
HAZ earnings for the last quarter are 0.94 EUR per share, whereas the estimation was 0.84 EUR resulting in a 11.51% surprise. The estimated earnings for the next quarter are 0.85 EUR per share. See more details about HAEMONETICS CORP earnings.
HAEMONETICS CORP revenue for the last quarter amounts to 301.00 M EUR despite the estimated figure of 296.24 M EUR. In the next quarter revenue is expected to reach 290.69 M EUR.
Yes, you can track HAEMONETICS CORP financials in yearly and quarterly reports right on TradingView.
HAZ stock has risen by 8.18% compared to the previous week, the month change is a 9.55% rise, over the last year HAEMONETICS CORP has showed a 15.44% increase.
HAZ net income for the last quarter is 28.30 M EUR, while the quarter before that showed 23.56 M EUR of net income which accounts for 20.12% change. Track more HAEMONETICS CORP financial stats to get the full picture.
Today HAEMONETICS CORP has the market capitalization of 4.37 B, it has decreased by 0.96% over the last week.
No, HAZ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HAZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HAEMONETICS CORP stock right from TradingView charts — choose your broker and connect to your account.
As of May 3, 2024, the company has 3.03 K employees. See our rating of the largest employees — is HAEMONETICS CORP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HAEMONETICS CORP technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HAEMONETICS CORP stock shows the strong buy signal. See more of HAEMONETICS CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HAEMONETICS CORP future price: according to them, HAZ price has a max estimate of 107.44 EUR and a min estimate of 82.22 EUR. Watch HAZ chart and read a more detailed HAEMONETICS CORP stock forecast: see what analysts think of HAEMONETICS CORP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HAEMONETICS CORP EBITDA is 265.97 M EUR, and current EBITDA margin is 22.29%. See more stats in HAEMONETICS CORP financial statements.